Until we are willing to accept the trade-offs and sacrifices needed to fix the system, the status quo will persist.
The idea of bringing down U.S. drug prices is universally popular. The hard choices, trade-offs and political fortitude needed to actually do it, however, are a harder sell. So here we are, with a drug-pricing plan so toothless that biotech shares soared as it was unveiled by President Donald Trump (recently). Continue reading